L. Thorlacius. 1,2, J. R. Ingram. 3, B. Villumsen4, S. Esmann1, J. S

Slides:



Advertisements
Similar presentations
Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.
Advertisements

Research Techniques Made Simple: Evaluating the Strength of Clinical Recommendations in the Medical Literature: GRADE, SORT, and AGREE Mayra Buainain de.
Core Outcome Domains for Eczema – Results of a Delphi Consensus Project Introduction Eczema is a chronic, relapsing, inflammatory skin disorder that affects.
Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.
BMH CLINICAL GUIDELINES IN EUROPE. OUTLINE Background to the project Objectives The AGREE Instrument: validation process and results Outcomes.
ACNE CORE OUTCOMES RESEARCH NETWORK Information for new members 11/2015.
Title of the Change Project
Role of The Physical Therapist in Critical Inquiry
Rachel Morell1, Simon Rosenbaum1,2 and Belinda J Parmenter1
Development of an electronic personal assessment questionnaire to capture the impact of living with a vascular condition: ePAQ-VAS Patrick Phillips, Elizabeth.
@hrbtmrn Intro and welcome.
F.M. Lewis, F.M. Tatnall, S.S. Velangi, C. B. Bunker,
Workforce Planning Framework
Changing the Game for Sjögren's Patients
September 7, 2018 Courtney Baird, MS
Health Services Research Postdoctoral Fellowship
Role of The Physical Therapist in Critical Inquiry
British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018 J.R. Ingram,1 F. Collier,2,3 D. Brown,4.
Laura J. Dixon1,2, Sara M. Witcraft1, Nancye K. McCowan2, & Robert T
Samine M. D. Ruff1; Kristiane A
Dan Perry, MD (Presented by Jennifer Laine, MD)
Validity of the EQ-5D in pemphigus vulgaris and foliaceus patients
To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in Hidradenitis Suppurativa Alicia Pavon Blanco,1.
Association of CCL2 with systemic inflammation in Schnitzler’s syndrome Karoline Krause, Robert Sabat, Ellen Witte-Händel, Anne Schulze, Viktoria Puhl,
A.D. Irvine1,2,3 and P. Mina-Osorio4
Systematic review of atopic dermatitis disease definition in studies using routinely-collected health data M.P. Dizon, A.M. Yu, R.K. Singh, J. Wan, M-M.
M. T. Svendsen1,2. ,, M. T. Ernst3. , K. E. Andersen1,2,4, F
Cancer is not a risk factor for bullous pemphigoid
Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway Ingrid Snekvik1,2, Tom I L Nilsen1, 3, Pål R Romundstad1,
Lack of Confidence Interval Reporting in Dermatology: A Call to Action
Fumaric acid esters in combination with a 6-week course of narrow-band UVB provides for an accelerated response as compared to fumaric acid esters monotherapy.
Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa J.R. Ingram*,
Effectiveness of Systemic Treatments for Pyoderma Gangrenosum: A Systematic Review of Observational Studies & Clinical Trials ACR Partridge1, JW Bai1,
High plasma 25-hydroxyvitamin D and high risk of non-melanoma skin cancer: a Mendelian randomisation study of individuals Ulrik C. Winsløw, Børge.
Gottlieb AB14, Christensen R2,15, Jemec GBE1
Validation and Reliability of a Disease-Specific Quality of Life Measure in Patients with Cutaneous Lupus Erythematosus: CLEQoL M.E. Ogunsanya,1 S.K. Cho,2.
Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among.
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials.
Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study P. Theut Riis, O.B. Pedersen,
Th17/Treg imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking, and autoimmune comorbidities B.C.
Cumulative exposure to biologics and risk of cancer in psoriasis patients: a meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom.
C.I.M. Busard, J.Y.C. Nolte, M.C. Pasch, Ph.I. Spuls
Applying the phenotype approach for rosacea to practice and research
Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis Kyriakou, A. Patsatsi,
K. A. Su,1,2 L. A. Habel,3 N. S. Achacoso,3 G. D. Friedman,3 M. M
Children with Facial Morphea Managing Everyday Life: A Qualitative Study Elaine Stasiulis1,2, Brenda Gladstone2, PhD, Katherine Boydell1,2,3, Christine.
Association between hidradenitis suppurativa and hospitalization for psychiatric disorders: A cross-sectional analysis of the National Inpatient Sample.
T. Tzellos1,2; H. Yang3; F. Mu3; B. Calimlim4; J. Signorovitch3
First Evaluation of the Behavioral Addiction Indoor Tanning Screener (BAITS) in a nationwide representative sample K. Diehl, T. Görig, E.W. Breitbart,
Use of emollients and topical glucocorticoids among adolescents with eczema: data from the population-based birth cohort BAMSE S. Lundin,1,2 C.F. Wahlgren,3,4.
F.M. Lewis, F.M. Tatnall, S.S. Velangi, C. B. Bunker,
A. Al-Janabi1, Z. K. Jabbar-Lopez2, C.E.M. Griffiths1, Z.Z.N. Yiu1
C. M. Olsen, L. F. Wilson, A. C. Green, N. Biswas, J. Loyalka, D. C
Surgical re-excision versus observation for histologically dysplastic nevi: a systematic review of associated clinical outcomes K.T. Vuong1, J. Walker2,
An App Supporting Psoriasis Patients Improves Adherence to Topical Treatment: A randomised controlled trial M.T. Svendsen,1,2,3 F. Andersen,1,4 K.H. Andersen,4.
Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Theodora Kanni,1 Othmar Zenker,2 Maria Habel,2 Niels Riedemann, 2 Evangelos.
Use of the hCONSORT Criteria as a Reporting Standard for Herbal Interventions for Common Dermatoses – A Systematic Review J. Ornelas, MD, MAS 1, E. Routt,
Atopic dermatitis, educational attainment and psychological functioning: a national cohort study Authors: Jevgenija Smirnova1,2, Laura von Kobyletzki1,3,
Prevalence and determinants of seborrhoeic dermatitis in a middle aged and elderly population: the Rotterdam Study M.G.H. Sanders, MD1, L.M. Pardo, MD,
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.
A multidimensional assessment of the burden of psoriasis: Results from a multinational dermatologist and patient survey C.E.M. Griffiths1, S.J. Jo2, L.
Kaposiform hemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon Yi Ji1, Kaiying Yang1, Suhua Peng1,
Patient reported outcome measures for facial skin cancer: a systematic review and evaluation of the quality of their measurement properties Tom Dobbs,
Proposal of a new scoring formula for the DLQI in psoriasis
RCT pilot study comparing localised immersion PUVA with localised narrowband ultraviolet B (NBUVB) for treatment of palmar hand eczema D. Brass1, T.
Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary.
Authors: S. Brill1, E. Sprecher2, F. J. D. Smith3, N. Geva4, H
Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs P. Soares, 1 K. Fidler, 1 J. Felton,
The prevalence of psychological co-morbidity in people with vitiligo: a systematic review and meta-analysis O. Osinubi, M.J. Grainge, L. Hong, A. Ahmed,
Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study  Jeanette.
Presentation transcript:

A Core Domain Set For Hidradenitis Suppurativa Trial Outcomes: An International Delphi Process L. Thorlacius*1,2, J. R. Ingram*3, B. Villumsen4, S. Esmann1, J. S. Kirby5, A. B. Gottlieb6, J. F. Merola7, R. Dellavalle8, S. M. Nielsen2, R. Christensen2, Amit Garg‡9, G. B. E. Jemec‡1 on behalf of the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) 1) Department of Dermatology, Zealand University Hospital, Roskilde; Health Sciences Faculty, University of Copenhagen, Denmark 2) Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark 3) Institute of Infection & Immunity, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK 4) The Patients' Association HS Denmark, Denmark 5) Department of Dermatology, Penn State Hershey Medical Center, Hershey, USA 6) Department of Dermatology, New York Medical College, Valhalla NY, USA 7) Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA 8) Dermatology Service, US Department of Veteran Affairs Medical Centre, Denver, USA 9) Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, New York, USA * The first two authors share co-first authorship ‡The last two authors share co-senior authorship British Journal of Dermatology. DOI: 10.111/bjd.16672

DEPARTMENT OF DERMATOLOGY, ZEALAND UNIVERSITY HOSPTIAL, DENMARK HISTORIC An international steering group consisting of researchers, clinicians and a patient research partner under the HISTORIC initiative has been formed to guide the development of the COS. The steering group consists of nine members; a patient research partner who is a board member of The HS Patients' Association in Denmark, two dermatologists with expertise in both HS research and clinical work; four dermatologists with a special interest in outcome measures in dermatology; a biostatistician from OMERACT experienced in COS development and a MD Ph.D. student.

Introduction What’s already known? Outcome measure instruments used for hidradenitis suppurativa are markedly heterogeneous, with 30 instruments recently found in 12 randomised trials. Lack of consensus regarding outcome measure instruments limits evidence synthesis and increases the risk of outcome reporting bias. A core domain set is an agreed minimum set that should be measured and reported in all clinical trials for a specific condition

Objective To achieve global multi-stakeholder consensus on a Core Outcome Set (COS) of domains regarding what to measure in clinical trials for HS.

Methods An international Delphi consensus project Using a multi-stakeholder approach, involving patients and healthcare professionals (HCPs) including dermatologists, surgeons, HS nurses, the pharmaceutical industry and medical regulators. Aiming to have a 1:1 ratio of patients:HCPs Patients were identified from patient associations and via dermatologists with a special interest in HS The meeting locations were planned for both Europe and North America to ensure that patient and HCP opinions from both continents were incorporated

Methods Phase 1: Identification of candidate items Systematic literature review Qualitative data from patient interviews and focus group studies Conducted in both Denmark and North America Interviews were conducted until the point of saturation (meaning, no new constructs or ideas are added) Survey of healthcare professionals Participants were asked to list all areas of importance regarding HS, related to any aspect of the disease or treatment of the disease

Methods Phase 2: Consensus process HS stakeholders participated in a Delphi process which included five anonymous e-Delphi rounds and four face-to-face consensus meetings to reach consensus on the final COS The combined list of potential items identified in Phase 1 were scored (1-3 = not important, 4-6 = important but not critical or 7-9 = critical) Items were discussed, rescored and then linked into over-arching domains and rediscussed Items were then included in COS or excluded, based on consensus opinion

DEPARTMENT OF DERMATOLOGY, ROSKILDE HOSPTIAL, DENMARK Phase 1 Phase 2

Patient global , Physician global Flare frequency and duration, Results Pain Physical Signs Anatomic location, Surface area, Total lesion count, Inflammatory lesion count, Number of abscesses, Number of inflamed nodules, Number of sinus tracts, Number of fistulae HS specific QOL Physical functioning, Psychological functioning, Psychosocial functioning, Emotional well-being, Ability to work or study Global assessment Patient global , Physician global Progression of course Flare frequency and duration, Time to recurrence Inner ring: the core set Domains and items that reached ‘consensus in’ for patients and HCPs Outer ring: Items that did not reach ‘consensus in’ but were marked as a specific research agenda or important in specific trials at consensus meetings Symptoms Biomarkers Time to heal Middle ring: Domains and items that reached ‘consensus in’ for patients or HCPs

Discussion The HISTORIC initiative has begun the process to develop a Core Outcome Set (COS) for HS trials The final core domain set includes five domains: pain physical signs hidradenitis suppurativa-specific quality of life global assessment progression of course A sixth domain, symptoms, was highly supported by patients and not by healthcare professionals; it was recommended for inclusion in the COS by the HISTORIC Steering Committee as an additional domain, given the importance of patient-reported domains

Conclusions What does this study add? Our study provides global multi-stakeholder consensus on core outcome domains for hidradenitis suppurativa The implementation of a COS for HS clinical trials should improve the interpretation and comparison of future studies testing interventions for HS and reduce the risk of outcome reporting bias and heterogeneity across studies After achieving consensus on what to measure in HS clinical trials, the next step for the HISTORIC initiative will be to reach consensus on the outcome measurement instruments best suited to measure each of the core domains in the COS

Call for correspondence Why not join the debate on this article through our correspondence section? Rapid responses should not exceed 350 words, four references and one figure Further details can be found here